Ioannis Vathiotis

790 total citations
57 papers, 516 citations indexed

About

Ioannis Vathiotis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ioannis Vathiotis has authored 57 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ioannis Vathiotis's work include Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (12 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Ioannis Vathiotis is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (12 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Ioannis Vathiotis collaborates with scholars based in Greece, United States and Australia. Ioannis Vathiotis's co-authors include Nikolaos Syrigos, Ηλίας Κοττέας, Andriani Charpidou, Georgia Gomatou, Konstantinos Syrigos, Evangelos Dimakakos, David L. Rimm, Niki Gavrielatou, Konstantinos N. Syrigos and Athanassios Argiris and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Ioannis Vathiotis

50 papers receiving 510 citations

Peers

Countries citing papers authored by Ioannis Vathiotis

Since Specialization

Citations

This map shows the geographic impact of Ioannis Vathiotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ioannis Vathiotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ioannis Vathiotis more than expected).

Fields of papers citing papers by Ioannis Vathiotis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ioannis Vathiotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ioannis Vathiotis. The network helps show where Ioannis Vathiotis may publish in the future.

Co-authorship network of co-authors of Ioannis Vathiotis

This figure shows the co-authorship network connecting the top 25 collaborators of Ioannis Vathiotis. A scholar is included among the top collaborators of Ioannis Vathiotis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ioannis Vathiotis. Ioannis Vathiotis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Prognostic Role of Different Blood Cell Count-to-Lymphocyte Ratios in Patients with Lung Cancer at Diagnosis 2025 ·Cancers ·Ουρανία Παπαϊωάννου, Oraianthi Fiste, (unknown), Fotios Sampsonas, Foteinos‐Ioannis Dimitrakopoulos, Αngelos Koutras, Ioannis Gkiozos, Ioannis Vathiotis, Ηλίας Κοττέας, (unknown)	0
2	Histologic Transformation in Cancer: The Path for Clinical Translation 2025 ·Cancer Discovery ·Ioannis Vathiotis, Avisek Banerjee, Utsav Sen, Felix Carl Saalfeld, Debdatta Halder, Andriani Charpidou, K. Syrigos, Hidehito Horinouchi, Ashutosh Tewari, Mark A. Dawson, Martin Wermke, Triparna Sen	0
3	Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma 2025 ·Clinical Lung Cancer ·(unknown), Nikolaos Syrigos, Kevin G. Blyth, Andriani Charpidou, Ioannis Vathiotis	0
4	Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer 2025 ·Nature Genetics ·Thazin Nwe Aung, James Monkman, Jonathan Warrell, Ioannis Vathiotis, (unknown), Niki Gavrielatou, Ioannis P. Trontzas, Chin Wee Tan, Aileen I. Fernandez, Myrto Moutafi, (unknown), Kurt A. Schalper, Konstantinos Syrigos, Roy S. Herbst, Arutha Kulasinghe, David L. Rimm	3
5	Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study 2024 ·Cancers ·(unknown), (unknown), Dimitra Stefanou, Ioannis Vathiotis, (unknown), (unknown), Evangelos Dimakakos, Nikolaos Syrigos	0
6	1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy 2023 ·Annals of Oncology ·(unknown), Jörg Möller, Sebastian Michels, Christian Grohé, Marcel Wiesweg, Christoph D. Schubart, (unknown), Frank Griesinger, Diego Kauffmann‐Guerrero, (unknown), Tobias R. Overbeck, (unknown), Gernot Rohde, Claas Wesseler, Ioannis Vathiotis, Rajwanth Veluswamy, (unknown), Sacha I. Rothschild, Petros Christopoulos, Martin Wermke	1
7	Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins 2023 ·Immunotherapy ·Sofia Vasilakaki, Ioannis Vathiotis, (unknown), Evangelos Dimakakos, Georgia Gomatou, Ηλίας Κοττέας	1
8	Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond 2023 ·Cancers ·Ioannis Vathiotis, Dimitrios Bafaloukos, Konstantinos N. Syrigos, George Samonis	15
9	B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma 2023 ·Annals of Oncology ·Niki Gavrielatou, (unknown), Aris Spathis, Μaria Anastasiou, Panagiota Economopoulou, (unknown), (unknown), Sylvie Rusakiewicz, Ioannis Vathiotis, Thazin Nwe Aung, (unknown), (unknown), Ioannis Kotsantis, Elena Vagia, Ioannis G. Panayiotides, David L. Rimm, George Coukos, Krisztián Homicskó, Periklis Foukas, Amanda Psyrri	29
10	Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck 2023 ·Journal for ImmunoTherapy of Cancer ·Jennifer M. Johnson, Ioannis Vathiotis, Larry A. Harshyne, (unknown), Voichita Bar Ad, Rita Axelrod, (unknown), Joseph Curry, David M. Cognetti, Adam Luginbuhl, Madalina Tuluc, Scott W. Keith, Mỹ G. Mahoney, Athanassios Argiris	9
11	2007P Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC) 2023 ·Annals of Oncology ·(unknown), (unknown), Ann Elizabeth Montgomery, (unknown), (unknown), Nikolaos Syrigos, (unknown), Andriani Charpidou, Ilias Georgakopoulos‐Soares, Ioannis Vathiotis	0
12	Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report 2023 ·Lung Cancer ·(unknown), Nikolaos Syrigos, (unknown), (unknown), (unknown), Andriani Charpidou, (unknown), Ilias Georgakopoulos‐Soares, Ioannis Vathiotis	1
13	A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305 2023 ·European Journal of Cancer ·Athanassios Argiris, Yael Flamand, P. Savvides, Jennifer M. Johnson, Ioannis Vathiotis, Marshall Levine, Shuli Li, Arlene A. Forastiere, Barbara Burtness	0
14	Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event 2022 ·Vaccines ·Nikolaos Syrigos, Αναστάσιος Κόλλιας, Dimitra Grapsa, (unknown), Konstantinos G. Kyriakoulis, Ioannis Vathiotis, Ηλίας Κοττέας, Ekaterini Syrigou	9
15	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities 2022 ·Vaccines ·Konstantinos Tsiakos, Niki Gavrielatou, Ioannis Vathiotis, Loukas Chatzis, (unknown), Garyphallia Poulakou, Ηλίας Κοττέας, Nikolaos Syrigos	3
16	CD24: A Novel Target for Cancer Immunotherapy 2022 ·Journal of Personalized Medicine ·(unknown), Nikolaos Syrigos, Andriani Charpidou, Ηλίας Κοττέας, Ioannis Vathiotis	61
17	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches 2022 ·Cancer Treatment Reviews ·Ioannis Vathiotis, Jennifer M. Johnson, Adam Luginbuhl, David M. Cognetti, Joseph Curry, Athanassios Argiris	2
18	Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade 2022 ·npj Precision Oncology ·Ioannis Vathiotis, Leonidas Salichos, Sandra Martínez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm	5
19	LYMPHEDEMA DURATION AS A PREDICTIVE FACTOR OF EFFICACY OF COMPLETE DECONGESTIVE THERAPY 2022 ·(unknown), George Papathanasiou, (unknown), Ioannis Vathiotis, Theodore Troupis, Evangelos Dimakakos	3
20	Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing 2019 ·Journal of Thoracic Disease ·Andriani Charpidou, Ioannis Vathiotis, Ioannis Gkiozos, Konstantinos Syrigos	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact